triazolam has been researched along with Diaphragmatic Paralysis in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The cause of death was respiratory paralysis produced by the additive effects of methomyl and nicotine shortly after consumption." | 1.33 | A fatal poisoning caused by methomyl and nicotine. ( Hashimoto, Y; Moriya, F, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moriya, F | 1 |
| Hashimoto, Y | 1 |
1 other study available for triazolam and Diaphragmatic Paralysis
| Article | Year |
|---|---|
A fatal poisoning caused by methomyl and nicotine.
Topics: Adult; Anti-Anxiety Agents; Bile; Forensic Medicine; Gas Chromatography-Mass Spectrometry; Humans; I | 2005 |